Core Viewpoint - The article highlights the recruitment of research positions in Professor Shu Yilai's team at Fudan University, focusing on groundbreaking research in gene therapy for hearing loss and the development of clinical applications [1][2]. Group 1: Professor Shu Yilai's Achievements - Professor Shu Yilai has developed gene therapy drugs for hearing loss and led the world's first clinical trial for congenital hearing loss, successfully restoring hearing and speech in multiple patients [1][2]. - His research has been published in prestigious journals such as The Lancet, BMJ, Nature Medicine, and JAMA Neurology, with significant recognition in the scientific community [1][2][3]. - He has received numerous awards, including the 48th ARO "Clinical Science Innovation Award," making him the first Asian scientist to achieve this honor [3]. Group 2: Research Focus and Innovations - The research team focuses on the mechanisms, prevention, and treatment of hearing loss, establishing a leading domestic and internationally advanced research platform [2]. - Key innovations include exploring the pathogenic mechanisms of common deafness genes and developing new strategies for gene therapy and drug delivery to the inner ear [2]. - The team has successfully developed candidate drugs for OTOF mutation-related hearing loss and conducted the first global clinical trial for congenital hearing loss [2]. Group 3: Recruitment Opportunities - The team is recruiting for positions including assistant researchers, postdoctoral researchers, and research assistants, with a focus on candidates with backgrounds in genetics, biology, clinical medicine, and related fields [4][5][11]. - Postdoctoral positions offer competitive salaries ranging from 300,000 to 500,000 CNY annually, with additional research rewards and opportunities for project leadership [8][9][12]. - The research assistant role requires a master's or bachelor's degree in life sciences or clinical medicine, with skills in molecular biology techniques and clinical research experience preferred [11]. Group 4: Research Platform and Resources - The research platform is supported by Fudan University's Biomedical Research Institute and the National Key Laboratory of Medical Neurobiology, providing a rich clinical resource [14]. - The affiliated hospital has a high patient volume, with over 3.29 million outpatient visits and more than 193,000 surgeries annually, making it a significant base for medical research and education [14]. - The hospital has established a gene and cell therapy center, focusing on innovative treatments for hearing loss and other conditions, and has received multiple awards for its research achievements [15][16].

Core Viewpoint - The Hong Kong stock market for innovative drugs has experienced a rally since the beginning of 2026, driven by positive clinical data from Arrowhead, which has boosted sentiment in the sector [1]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (159570) has shown strong performance, with a nearly 2% increase and a trading volume exceeding 9 billion, indicating high trading activity [6]. - As of January 7, 2026, the ETF's latest scale has surpassed 24.7 billion, leading its peers in the same category [6]. - The majority of the weighted stocks in the ETF index have shown positive performance, with notable increases from companies like Sanofi and Innovent Biologics [2]. Group 2: Company News - Strong Brain Technology, a brain-computer interface "unicorn," has completed a financing round of 2 billion, second only to Musk's Neuralink [1]. - Insilico Medicine, an AI-driven pharmaceutical company, has announced a long-term collaboration with Sihuan Pharmaceutical for anti-tumor drug development, with a total cooperation amount of 888 million [1]. Group 3: Industry Trends - The innovative drug industry is expected to continue its upward trend, with catalysts on the horizon. The market anticipates a busy period for business development (BD) transactions and data disclosures in early 2026 [4]. - The upcoming J.P. Morgan Healthcare Conference is expected to attract over 8,000 global participants, showcasing advancements in biotechnology, pharmaceuticals, and medical devices [5]. - Three major trends are emerging in the industry: the continued rise of gene and cell therapies, deep integration of AI in pharmaceuticals, and the rise of emerging market players [7]. Group 4: Investment Insights - The average total package for top multinational corporations (MNCs) purchasing innovative drugs or technology platforms from China in 2025 is 2.756 billion, indicating a willingness to pay higher prices for Chinese innovations [8]. - The focus of MNCs is shifting from merely acquiring products to obtaining platforms and time, emphasizing the importance of technology platforms that can produce new molecules [10]. - Investment logic suggests that MNCs are willing to pay premiums for clinically validated assets, particularly those that can fill pipeline gaps and provide immediate revenue [11].

Group 1: AI Evolution - AI has transitioned from being a remarkable "tool" to becoming a collaborative "partner" in various applications, enhancing productivity and creating new mixed-task models [3][5] - Significant advancements in AI models occurred throughout the year, including the release of Claude 3.7 Sonnet, Manus, and Gemini 3 series, showcasing improvements in multi-modal capabilities [4] - The industry is moving towards a new evaluation system that reflects AI's real-world problem-solving abilities, focusing on quantifiable ROI from AI investments [6] Group 2: Embodied Intelligence - 2025 marked the commercialization of embodied intelligence, with significant technological breakthroughs such as RoboOS and RoboBrain, lowering development barriers [9][10] - The evolution of AI is shifting towards cognitive intelligence, emphasizing the importance of real-world training and iteration for intelligent systems [9] - Embodied intelligence is enhancing human capabilities in various fields, including industrial applications and emotional companionship through AI toys and digital pets [10][11] Group 3: Healthcare Innovations - The biotech sector in China experienced explosive growth, with innovations in gene editing and domestic drugs gaining FDA approval, marking a shift from follower to leader in global healthcare [16][19] - AI is deeply integrated into life sciences, transforming drug development and precision medicine, thus reshaping the healthcare landscape [22] - High-end medical devices are advancing rapidly, with domestic innovations addressing critical needs in minimally invasive surgeries [20] Group 4: Consumer Market Dynamics - Emotional value has become a core driver of consumer behavior, with brands needing to provide deeper emotional resonance beyond basic functionality [24][26] - The retail landscape is evolving into a content-driven model, where physical stores must offer immersive experiences to attract customers [28] - Consumers are increasingly seeking seamless, personalized experiences across multiple channels, necessitating a focus on holistic customer journeys [28][29] Group 5: Entrepreneurial Mindset - Entrepreneurs are encouraged to break free from past successes that may hinder innovation, embracing unconventional thinking to navigate resource constraints [30] - Building empathy and transferable skills is essential for adapting to industry changes and enhancing team collaboration [32] - Sustainable energy management is crucial for entrepreneurs, balancing personal well-being with business growth to ensure long-term success [38]